Expression and function of P2X7 receptor and CD39/Entpd1 in patients with type 2 diabetes and their association with biochemical parameters

Cellular Immunology

Volumn 269, Issue 2, 2011, Pages 135-143

  García Hernández, Mariana H ^a,d   Portales Cervantes, Liliana ^a,b   Cortez Espinosa, Nancy ^a   Vargas Morales, Juan M ^a   Fritche Salazar, Juan F ^c   Rivera López, Emmanuel ^c   Rodríguez Rivera, Javier G ^c   Quezada Calvillo, Roberto ^b   Portales Pérez, Diana P ^a,b  

^a UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^c Unidad de Medicina Interna y Endocrinologia del Hospital Central Dr Ignacio Morones Prieto SLP   (Mexico)

^d INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

CD39 Entpd1; CD62L; IL 1 ; Immune regulation; Inflammation; P2X7 receptor

Indexed keywords

BEZAFIBRATE; CD14 ANTIGEN; CD19 ANTIGEN; CD39 ANTIGEN; CD4 ANTIGEN; CORTICOSTEROID; ENALAPRIL; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INTERLEUKIN 17; METFORMIN; PHOSPHATASE; PROTEIN ENTPD 1; PURINERGIC P2X7 RECEPTOR; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATE; APYRASE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INTERLEUKIN 1BETA; L SELECTIN; LEUKOCYTE ANTIGEN; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PURINERGIC P2X4 RECEPTOR;

ADULT; ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; MALE; METABOLIC REGULATION; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; BLOOD; DRUG EFFECT; ENZYMOLOGY; MIDDLE AGED; MONONUCLEAR CELL;

ADENOSINE TRIPHOSPHATE; ADULT; ANTIGENS, CD; APYRASE; BLOOD GLUCOSE; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INTERLEUKIN-17; INTERLEUKIN-1BETA; L-SELECTIN; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; RECEPTORS, PURINERGIC P2X4; RECEPTORS, PURINERGIC P2X7; YOUNG ADULT;

EID: 79957648871     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2011.03.022     Document Type: Article

References (64)

1. Wellen K.E., Hotamisligil G.S. Inflammation, stress, and diabetes. J. Clin. Invest. 2005, 115:1111-1119.
2. Skrha J. Type 2 diabetes mellitus as a subclinical inflammation. Cas. Lek. Cesk. 2010, 149:277-281.
3. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
4. Eldar-Finkelman H., Krebs E.G. Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proc. Natl. Acad. Sci. USA 1997, 94:9660-9664.
5. Ravichandran L.V., Esposito D.L., Chen J., Quon M.J. Protein kinase C-zeta phosphorylates insulin receptor substrate-1 and impairs its ability to activate phosphatidylinositol 3-kinase in response to insulin. J. Biol. Chem. 2001, 276:3543-3549.
6. Lee Y.H., Giraud J., Davis R.J., White M.F. c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J. Biol. Chem. 2003, 278:2896-2902.
7. De F.K., Roth R.A. Modulation of insulin receptor substrate-1 tyrosine phosphorylation and function by mitogen-activated protein kinase. J. Biol. Chem. 1997, 272:31400-31406.
8. Gao Z., Hwang D., Bataille F., Lefevre M., York D., Quon M.J., Ye J. Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J. Biol. Chem. 2002, 277:48115-48121.
9. Rui L., Aguirre V., Kim J.K., Shulman G.I., Lee A., Corbould A., Dunaif A., White M.F. Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J. Clin. Invest. 2001, 107:181-189.
10. Jager J., Gremeaux T., Cormont M., Le Marchand-Brustel Y., Tanti J.F. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 2007, 148:241-251.
11. Senn J.J., Klover P.J., Nowak I.A., Zimmers T.A., Koniaris L.G., Furlanetto R.W., Mooney R.A. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J. Biol. Chem. 2003, 278:13740-13746.
12. Rui L., Yuan M., Frantz D., Shoelson S., White M.F. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J. Biol. Chem. 2002, 277:42394-42398.
13. Dandona P., Aljada A., Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004, 25:4-7.
14. Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance. J. Clin. Invest. 2006, 116:1793-1801.
15. Kim J.J., Sears D.D. TLR4 and Insulin Resistance. Gastroenterol. Res. Pract. 2010, 212563. pii: 212563. Epub;%2010 Aug 10.
16. Ballou L.R., Laulederkind S.J., Rosloniec E.F., Raghow R. Ceramide signalling and the immune response. Biochim. Biophys. Acta 1996, 1301:273-287.
17. Holland W.L., Brozinick J.T., Wang L.P., Hawkins E.D., Sargent K.M., Liu Y., Narra K., Hoehn K.L., Knotts T.A., Siesky A., Nelson D.H., Karathanasis S.K., Fontenot G.K., Birnbaum M.J., Summers S.A. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 2007, 5:167-179.
18. Schmitz-Peiffer C. Targeting ceramide synthesis to reverse insulin resistance. Diabetes 2010, 59:2351-2353.
19. Labasi J.M., Petrushova N., Donovan C., McCurdy S., Lira P., Payette M.M., Brissette W., Wicks J.R., Audoly L., Gabel C.A. Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J. Immunol. 2002, 168:6436-6445.
20. Di V.F. The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. Immunol. Today 1995, 16:524-528.
21. Surprenant A., Rassendren F., Kawashima E., North R.A., Buell G. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 1996, 272:735-738.
22. Torres G.E., Egan T.M., Voigt M.M. Hetero-oligomeric assembly of P2X receptor subunits. Specificities exist with regard to possible partners. J. Biol. Chem. 1999, 274:6653-6659.
23. Guo C., Masin M., Qureshi O.S., Murrell-Lagnado R.D. Evidence for functional P2X4/P2X7 heteromeric receptors. Mol. Pharmacol. 2007, 72:1447-1456.
24. Zhang X.J., Zheng G.G., Ma X.T., Lin Y.M., Song Y.H., Wu K.F. Effects of various inducers on the expression of P2X7 receptor in human peripheral blood mononuclear cells. Sheng Li Xue. Bao. 2005, 57:193-198.
25. Coutinho-Silva R., Persechini P.M., Bisaggio R.D., Perfettini J.L., Neto A.C., Kanellopoulos J.M., Motta-Ly I., Dautry-Varsat A., Ojcius D.M. P2Z/P2X7 receptor-dependent apoptosis of dendritic cells. Am. J. Physiol. 1999, 276:C1139-C1147.
26. Hickman S.E., el K.J., Greenberg S., Schieren I., Silverstein S.C. P2Z adenosine triphosphate receptor activity in cultured human monocyte-derived macrophages. Blood 1994, 84:2452-2456.
27. Lister M.F., Sharkey J., Sawatzky D.A., Hodgkiss J.P., Davidson D.J., Rossi A.G., Finlayson K. The role of the purinergic P2X7 receptor in inflammation. J. Inflamm. (Lond.) 2007, 4-5:5.
28. Gu B., Bendall L.J., Wiley J.S. Adenosine triphosphate-induced shedding of CD23 and L-selectin (CD62L) from lymphocytes is mediated by the same receptor but different metalloproteases. Blood 1998, 92:946-951.
29. Solini A., Chiozzi P., Morelli A., Adinolfi E., Rizzo R., Baricordi O.R., Di V.F. Enhanced P2X7 activity in human fibroblasts from diabetic patients: a possible pathogenetic mechanism for vascular damage in diabetes. Arterioscler. Thromb. Vasc. Biol. 2004, 24:1240-1245.
30. Dombrowski K.E., Ke Y., Brewer K.A., Kapp J.A. Ecto-ATPase: an activation marker necessary for effector cell function. Immunol. Rev. 1998, 161(111-118):111-118.
31. Kansas G.S., Wood G.S., Tedder T.F. Expression, distribution, and biochemistry of human CD39. Role in activation-associated homotypic adhesion of lymphocytes. J. Immunol. 1991, 146:2235-2244.
32. Levesque S.A., Kukulski F., Enjyoji K., Robson S.C., Sevigny J. NTPDase1 governs P2X7-dependent functions in murine macrophages. Eur. J. Immunol. 2010, 40:1473-1485.
33. Imai M., Goepfert C., Kaczmarek E., Robson S.C. CD39 modulates IL-1 release from activated endothelial cells. Biochem. Biophys. Res. Commun. 2000, 270:272-278.
34. Goepfert C., Imai M., Brouard S., Csizmadia E., Kaczmarek E., Robson S.C. CD39 modulates endothelial cell activation and apoptosis. Mol. Med. 2000, 6:591-603.
35. Deaglio S., Dwyer K.M., Gao W., Friedman D., Usheva A., Erat A., Chen J.F., Enjyoji K., Linden J., Oukka M., Kuchroo V.K., Strom T.B., Robson S.C. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 2007, 204:1257-1265.
36. Fletcher J.M., Lonergan R., Costelloe L., Kinsella K., Moran B., O'Farrelly C., Tubridy N., Mills K.H. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J. Immunol. 2009, 183:7602-7610.
37. Enjyoji K., Kotani K., Thukral C., Blumel B., Sun X., Wu Y., Imai M., Friedman D., Csizmadia E., Bleibel W., Kahn B.B., Robson S.C. Deletion of cd39/entpd1 results in hepatic insulin resistance. Diabetes 2008, 57:2311-2320.
38. Jagannathan-Bogdan M., McDonnell M.E., Shin H., Rehman Q., Hasturk H., Apovian C.M., Nikolajczyk B.S. Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. J. Immunol. 2011, 186:1162-1172.
39. Kimura A., Naka T., Kishimoto T. IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc. Natl. Acad. Sci. USA 2007, 104:12099-12104.
40. Solini A., Chiozzi P., Falzoni S., Morelli A., Fellin R., Di V.F. High glucose modulates P2X7 receptor-mediated function in human primary fibroblasts. Diabetologia 2000, 43:1248-1256.
41. Meier C.A., Bobbioni E., Gabay C., Assimacopoulos-Jeannet F., Golay A., Dayer J.M. IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin?. J. Clin. Endocrinol. Metab. 2002, 87:1184-1188.
42. Ruotsalainen E., Salmenniemi U., Vauhkonen I., Pihlajamaki J., Punnonen K., Kainulainen S., Laakso M. Changes in inflammatory cytokines are related to impaired glucose tolerance in offspring of type 2 diabetic subjects. Diabetes Care 2006, 29:2714-2720.
43. Marculescu R., Endler G., Schillinger M., Iordanova N., Exner M., Hayden E., Huber K., Wagner O., Mannhalter C. Interleukin-1 receptor antagonist genotype is associated with coronary atherosclerosis in patients with type 2 diabetes. Diabetes 2002, 51:3582-3585.
44. Glas R., Sauter N.S., Schulthess F.T., Shu L., Oberholzer J., Maedler K. Purinergic P2X7 receptors regulate secretion of interleukin-1 receptor antagonist and beta cell function and survival. Diabetologia 2009, 52:1579-1588.
45. Shimabukuro M., Koyama K., Lee Y., Unger R.H. Leptin- or troglitazone-induced lipopenia protects islets from interleukin 1beta cytotoxicity. J. Clin. Invest. 1997, 100:1750-1754.
46. Ward J.R., West P.W., Ariaans M.P., Parker L.C., Francis S.E., Crossman D.C., Sabroe I., Wilson H.L. Temporal interleukin-1beta secretion from primary human peripheral blood monocytes by P2X7-independent and P2X7-dependent mechanisms. J. Biol. Chem. 2010, 285:23147-23158.
47. Perregaux D.G., McNiff P., Laliberte R., Conklyn M., Gabel C.A. ATP acts as an agonist to promote stimulus-induced secretion of IL-1 beta and IL-18 in human blood. J. Immunol. 2000, 165:4615-4623.
48. Prentki M., Nolan C.J. Islet beta cell failure in type 2 diabetes. J. Clin. Invest. 2006, 116:1802-1812.
49. Lenertz L.Y., Wang Z., Guadarrama A., Hill L.M., Gavala M.L., Bertics P.J. Mutation of putative N-linked glycosylation sites on the human nucleotide receptor P2X7 reveals a key residue important for receptor function. Biochemistry 2010, 49:4611-4619.
50. Komura T., Sakai Y., Honda M., Takamura T., Matsushima K., Kaneko S. CD14+ monocytes are vulnerable and functionally impaired under endoplasmic reticulum stress in patients with type 2 diabetes. Diabetes 2010, 59:634-643.
51. Schroder K., Zhou R., Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger?. Science 2010, 327:296-300.
52. Kanneganti T.D., Lamkanfi M., Kim Y.G., Chen G., Park J.H., Franchi L., Vandenabeele P., Nunez G. Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of Toll-like receptor signaling. Immunity 2007, 26:433-443.
53. Lamkanfi M., Dixit V.M. Inflammasomes: guardians of cytosolic sanctity. Immunol. Rev. 2009, 227:95-105.
54. Rydberg T., Jonsson A., Karlsson M.O., Melander A. Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. Br. J. Clin. Pharmacol. 1997, 43:373-381.
55. Adams W.J., Skinner G.S., Bombardt P.A., Courtney M., Brewer J.E. Determination of glyburide in human serum by liquid chromatography with fluorescence detection. Anal. Chem. 1982, 54:1287-1291.
56. Lamkanfi M., Mueller J.L., Vitari A.C., Misaghi S., Fedorova A., Deshayes K., Lee W.P., Hoffman H.M., Dixit V.M. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J. Cell Biol. 2009, 187:61-70.
57. Potocnik A.J., Kinne R., Menninger H., Zacher J., Emmrich F., Kroczek R.A. Expression of activation antigens on T cells in rheumatoid arthritis patients. Scand. J. Immunol. 1990, 31:213-224.
58. Filippini A., Taffs R.E., Agui T., Sitkovsky M.V. Ecto-ATPase activity in cytolytic T-lymphocytes. Protection from the cytolytic effects of extracellular ATP. J. Biol. Chem. 1990, 265:334-340.
59. Nakarai H., Yamashita A., Nagayasu S., Iwashita M., Kumamoto S., Ohyama H., Hata M., Soga Y., Kushiyama A., Asano T., Abiko Y., Nishimura F. Adipocyte-macrophage interaction may mediate LPS-induced low-grade inflammation: potential link with metabolic complications. Innate. Immun. 2011.
60. Borsellino G., Kleinewietfeld M., Di M.D., Sternjak A., Diamantini A., Giometto R., Hopner S., Centonze D., Bernardi G., Dell'Acqua M.L., Rossini P.M., Battistini L., Rotzschke O., Falk K. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007, 110:1225-1232.
61. Wilson N.J., Boniface K., Chan J.R., McKenzie B.S., Blumenschein W.M., Mattson J.D., Basham B., Smith K., Chen T., Morel F., Lecron J.C., Kastelein R.A., Cua D.J., McClanahan T.K., Bowman E.P., de Waal M.R. Development cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 2007, 8:950-957.
62. Ouyang W., Kolls J.K., Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008, 28:454-467.
63. Metzger K., Fremont M., Roelant C., De M.K. Lower frequency of IL-17F sequence variant (His161Arg) in chronic fatigue syndrome patients. Biochem. Biophys. Res. Commun. 2008, 376:231-233.
64. Atarashi K., Nishimura J., Shima T., Umesaki Y., Yamamoto M., Onoue M., Yagita H., Ishii N., Evans R., Honda K., Takeda K. ATP drives lamina propria T(H)17 cell differentiation. Nature 2008, 455:808-812.